← Back to Search

Central Nervous System Stimulant

3 - Methylphenidate and Citalopram for Depression

Phase 4
Waitlist Available
Led By Helen Lavretsky, MD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured at baseline and week 16
Awards & highlights
Drug Has Already Been Approved
Approved for 5 Other Conditions
Pivotal Trial
All Individual Drugs Already Approved

Summary

This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured at baseline and week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at baseline and week 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16
Secondary study objectives
Quality of Life Assessment

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

3Treatment groups
Active Control
Group I: 2 - Methylphenidate and placeboActive Control2 Interventions
Participants will take a combination of methylphenidate and placebo for 16 weeks
Group II: 1 - Citalopram and placeboActive Control2 Interventions
Participants will take a combination of citalopram and placebo for 16 weeks
Group III: 3 - Methylphenidate and CitalopramActive Control2 Interventions
Participants will take a combination of methylphenidate and citalopram for 16 weeks

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,558 Previous Clinical Trials
10,258,488 Total Patients Enrolled
105 Trials studying Depression
49,225 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,892 Previous Clinical Trials
2,722,546 Total Patients Enrolled
696 Trials studying Depression
260,615 Patients Enrolled for Depression
Helen Lavretsky, MDPrincipal InvestigatorUniversity of California, Los Angeles
2 Previous Clinical Trials
20 Total Patients Enrolled
~10 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top